Atazanavir for treatment of HIV infection in clinical routine: Efficacy, pharmacokinetics and safety

European Journal of Medical Research

Volumn 10, Issue 1, 2005, Pages 7-10

  Feldt, T ^a   Oette, Mark ^a   Kroidl, A ^a   Gobels K ^a   Leidel, R ^a   Sagir, A ^a   Kuschak, D ^b   Haussinger D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Medical Laboratories   (Germany)

Author keywords

Atazanavir; HAART; HIV; Therapeutic drug monitoring

Indexed keywords

A 86093; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; JAUNDICE; LIPODYSTROPHY; LYMPHOCYTE COUNT; NAUSEA; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL CHEMISTRY TESTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEMATOLOGIC TESTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES; RITONAVIR; TREATMENT OUTCOME;

EID: 14544295822     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM (2003). Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63:741-753
2. Agarwala S (2003). Characterization of the steady state pharmacokinetic profile of atazanavir beyond the 24h dosing interval. 2nd IAS, Paris13.16.07.03. Abstract 845
3. Barbaro, G (2003). HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc Res 60:87-95
4. Burger DM, Hugen PW, Aarnoutse RE, et al (2003). Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 25:73-80
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093-2099
6. Carr A (2003). Cardiovascular risk factors in HIV-infected patients. J Acquir Immune Defic Syndr 34(Suppl 1): S73-S78.
7. Goldsmith DR, Perry CM (2003). Atazanavir. Drugs 63:1679-1693
8. Haerter G, Manfras BJ, Mueller M, Kern P, Trein A (2004). Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 18:952-955
9. Kuschak D, Mauss S, Schmutz G, Gantke B (2001). Simultaneous determination of the new HIV protease inhibitor Lopinavir (ABT 378) and of Indinavir, Amprenavir, Saquinavir, Ritonavir (ABT 538) and Nelfinavir in human plasma by gradient HPLC. Clin Lab 47:471-477
10. Palella FJ Jr, Delaney KM, Moorman AC, et al (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 338:853-860
11. Taburet A-M, Piketty C, Chazallon C, et al (2004). Interactions between Atazanavir-Ritonavir and Tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 48:2091-2096